Humana (NYSE:HUM) Raised to “Outperform” at Raymond James Financial

Humana (NYSE:HUM) was upgraded by equities research analysts at Raymond James Financial from a “market perform” rating to an “outperform” rating in a report issued on Monday, Marketbeat.com reports. The firm currently has a $520.00 target price on the insurance provider’s stock. Raymond James Financial’s price target points to a potential upside of 23.46% from the company’s current price.

Other research analysts have also recently issued reports about the stock. Weiss Ratings upgraded shares of Humana from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, August 14th. Morgan Stanley raised shares of Humana from an “underweight” rating to an “overweight” rating in a research note on Friday. Barclays lifted their price objective on shares of Humana from $515.00 to $582.00 and gave the company an “overweight” rating in a report on Friday. HSBC cut shares of Humana to a “hold” rating in a research report on Thursday, July 30th. Finally, Leerink Partners upgraded shares of Humana from a “market perform” rating to an “outperform” rating and set a $513.00 target price on the stock in a research note on Thursday, July 30th. Twenty-one investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $453.30.

Humana Price Performance

HUM opened at $421.20 on Monday. The business has a fifty day moving average of $390.92 and a 200 day moving average of $338.28. The stock has a market cap of $50.58 billion, a P/E ratio of 25.20, a PEG ratio of 2.67 and a beta of 0.74. The company has a quick ratio of 1.74, a current ratio of 1.74 and a debt-to-equity ratio of 0.62. Humana has a 52-week low of $163.11 and a 52-week high of $456.50.

Humana (NYSE:HUM) last released its earnings results on Wednesday, July 29th. The insurance provider reported $7.61 earnings per share for the quarter, topping analysts’ consensus estimates of $7.27 by $0.34. Humana had a return on equity of 11.20% and a net margin of 0.88%. The business had revenue of $40.89 billion for the quarter, compared to analyst estimates of $40.58 billion. During the same quarter last year, the firm posted $6.27 earnings per share. The business’s revenue was up 26.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that Humana will post 9.03 EPS for the current year.

Hedge Funds Weigh In On Humana

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. acquired a new stake in Humana in the second quarter worth about $4,138,160,000. Pzena Investment Management LLC grew its stake in shares of Humana by 34.3% during the first quarter. Pzena Investment Management LLC now owns 5,470,982 shares of the insurance provider’s stock worth $948,614,000 after acquiring an additional 1,398,774 shares during the last quarter. Legal & General Group Plc acquired a new position in shares of Humana during the second quarter valued at about $329,760,000. Barrow Hanley Mewhinney & Strauss LLC acquired a new position in shares of Humana during the second quarter valued at about $314,922,000. Finally, Wellington Management Group LLP increased its holdings in shares of Humana by 7.3% during the second quarter. Wellington Management Group LLP now owns 765,355 shares of the insurance provider’s stock valued at $304,014,000 after acquiring an additional 52,004 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

More Humana News

Here are the key news stories impacting Humana this week:

• Positive Sentiment: Medicare Advantage ratings improved significantly. Humana expects approximately 95% of its members to be enrolled in plans rated four stars or better for 2027, compared with about 20% previously. The improvement could support higher quality-bonus payments, more competitive benefits and stronger membership economics in future years. Humana Hits 95% Four-Star Coverage: What it Means for HUM
• Positive Sentiment: BlackRock partnership supports CenterWell expansion. Humana agreed to form a joint venture with funds managed by BlackRock to manage nearly 150 CenterWell Senior Primary Care clinics. The transaction is intended to provide capital and operating support while allowing Humana to retain a minority interest and participate in the growth of its senior-care platform. Humana Announces New Strategic Joint Venture with BlackRock
• Positive Sentiment: Analyst sentiment and trading activity were supportive. Mizuho raised its price target to $495 and maintained an outperform rating, while Raymond James upgraded Humana to outperform with a $520 target. Call-option activity also rose above its average level, indicating increased bullish speculation. Humana Analyst Forecasts
• Neutral Sentiment: Near-term direction depends on upcoming earnings. Humana will report third-quarter 2026 results on November 6, making medical-cost trends, Medicare Advantage performance and updated guidance the next major catalysts. Humana Third-Quarter 2026 Earnings Date
• Negative Sentiment: Valuation and legal headlines may temper enthusiasm. After its substantial rally, Humana trades at a relatively high earnings multiple, increasing sensitivity to profit-taking or any disappointing guidance. Separately, a law firm is soliciting shareholders over alleged insider fiduciary-duty violations; the announcement does not establish wrongdoing but adds headline risk. Humana Shareholder Investigation

About Humana

Humana Inc is a health and well-being company headquartered in Louisville, Kentucky. Founded in 1961, the company began as a nursing home operator before expanding into hospitals and health insurance. Today, Humana primarily provides health insurance products and healthcare services for older adults, individuals, military families and other members in the United States.

Humana’s insurance business offers Medicare Advantage, Medicare Supplement and prescription drug plans, as well as Medicaid coverage in select markets.